通心络胶囊治疗冠心病心绞痛的系统评价再评价  

An Overview of Systematic Reviews of Tongxinluo Capsule in the Treatment of Coronary Heart Disease Angina Pectoris

作　　者：张宁[1] 李欣欣[1] 刘璐瑶 焦雪妍 张艺凡 郭娇[2] 兰真真 刘新灿[2] ZHANG Ning;LI Xinxin;LIU Luyao;JIAO Xueyan;ZHANG Yifan;GUO Jiao;LAN Zhenzhen;LIU Xincan(Henan University of Chinese Medicine,Zhengzhou 450046,Henan,China)

机构地区：[1]河南中医药大学,郑州450046 [2]河南中医药大学第一附属医院,郑州450099

出　　处：《中西医结合心脑血管病杂志》2022年第22期4039-4044,共6页Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease

基　　金：2018年河南省中医管理局国家中医临床研究基地科研专项课题(No.2018JDZX008);2021年度河南省青年人才托举工程项目(No.2021HYTP057)。

摘　　要：目的对通心络胶囊治疗冠心病心绞痛的系统评价/Meta分析进行再评价。方法检索建库至2022年5月1日中国知网(CNKI)、万方(WanFang Data)、维普(VIP)、PubMed、EMbase、the Cochrane Library数据库发表的通心络胶囊治疗冠心病心绞痛的系统评价/Meta分析,由2位研究员筛选符合纳入与排除标准的系统评价,提取资料,交叉核对。采用AMSTAR2量表进行方法学质量评价,采用GRADE工具行证据等级评价。结果共纳入9篇系统评价/Meta分析。AMSTARE2评价结果显示所有报告均为极低级质量。GEADE分级结果显示,57个结局指标中,证据质量为中级的指标3个,证据质量为低级的指标12个,证据质量为极低级的指标42个,研究的局限性和发表偏倚为主要降级原因。结论通心络胶囊治疗冠心病心绞痛的相关系统评价/Meta分析的方法学质量总体不高,结论的证据水平普遍较低,未来需要严格遵循循证医学科研设计要求的临床试验和系统评价以提供更高质量的证据。Objective To review the evidence of the efficacy of Tongxinluo Capsule in the treatment of angina pectoris.Methods CNKI,WanFang Data,VIP,PubMed,EMbase,and the Cochrane Library databases were searched to collect the systematic reviews(SRs)of Tongxinluo Capsule in the treatment of angina pectoris from the inception to May 1st,2022.Two reviewers independently screened literature and extracted data,then AMSTAR2 tool was used to assess the papers quality and the methodological quality of included studies.The GRADE tool was used to grade the evidence quality of outcomes included in the SRs.Results A total of 9 SRs/Meta analyses were included.The results of AMSTAR 2 assessment showed all SRs/Meta analyses with very low quality.The results of GRADE classification showed that there were 57 outcome indicators,of which 3 outcome indicators with intermediate evidence quality,12 outcome indicators with low evidence quality,and the rest with very low quality.The reason for these results were mainly owing to research limitations and publication bias.Conclusion The methodological quality of the SRs/Meta analyses of Tongxinluo Capsule for the treatment of coronary heart disease angina pectoris is generally not high,and the level of evidence for the conclusion is generally low.So more high quality experiments and strict designed SRs are needed in the future to provide higher quality evidences for the clinician.

关 键 词：冠心病 心绞痛 通心络胶囊 系统评价再评价 AMSTAR2量表 

分 类 号：R259[医药卫生—中西医结合]